ABBV

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

Retrieved on: 
Freitag, Mai 24, 2024
News, HER2, Investment, Pfizer, Chimera, Hallucination, Pancreas, Blood, Pancreatic cancer, Breast cancer, Anxiety, Medicine, Proteolysis, Therapy, TSX, Nucleic acid thermodynamics, Survival, TIL, PALM, ONC, TILS, Magnetic resonance imaging, ABBV, NASAR, MD, Gemcitabine, PFE, Immunotherapy, PDAC, ARVN, DSM-IV codes, Safety, FOLFIRINOX, Psychiatry, Research, Cancer, Rhinitis, ASCO, Society, Patient, Doctor of Philosophy, DNA, Prevalence, Diagnosis, Growth, Social media, Pancreatic Cancer Action Network, Abstract, Personalized medicine, ESMO, Oncolytics Biotech, Classic, Oncology, Annual general meeting, Pharmaceutical industry

With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts.

Key Points: 
  • With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts.
  • The report said: “This growth is driven by increasing instances of pancreatic cancer and higher investments in pancreatic oncology research.
  • In recent years, the pancreatic cancer market has experienced steady growth, largely driven by the increasing prevalence of pancreatic cancer cases globally.
  • BioSpace concluded: “Several notable trends are shaping the pancreatic cancer market.

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP

Retrieved on: 
Samstag, Mai 11, 2024
Class Action Lawsuit, Professional Services, Legal, ABBV, KSF, Sale, AbbVie

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Retrieved on: 
Montag, Mai 13, 2024
Hallucination, Psychiatry, Research, Exercise, Therapy, Classic, ABBV, AbbVie, DSM-IV codes, Anxiety, Pharmaceutical industry

NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens.

Key Points: 
  • NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders.
  • Classic psychedelic compounds provide novel mechanisms to address mental health disorders, and some have shown promising clinical efficacy where other treatments have been ineffective.
  • These new compounds hold substantial promise for treating a variety of psychiatric conditions, including mood and anxiety disorders.
  • Under terms of the agreement, AbbVie and Gilgamesh have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

AbbVie to Present at the Bank of America Securities Healthcare Conference

Retrieved on: 
Montag, Mai 6, 2024
ABBV, Bank, Conference, AbbVie

NORTH CHICAGO, Ill., May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.

Key Points: 
  • NORTH CHICAGO, Ill., May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.
  • Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 12:40 p.m. Central time.
  • A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com .
  • An archived edition of the session will be available later that day.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

Retrieved on: 
Freitag, April 12, 2024
Class Action Lawsuit, Professional Services, Legal, ABBV, News, AbbVie, Research, GPM, IPR, GAAP, Person

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV ) investors concerning the Company’s possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV ) investors concerning the Company’s possible violations of the federal securities laws.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense.
  • Whistleblower Notice: Persons with non-public information regarding AbbVie should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

Retrieved on: 
Freitag, April 12, 2024
Legal, Professional Services, AbbVie, Suite, Research, IPR, Telephone, ABBV, GAAP, News

Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV ) investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV ) investors concerning the Company’s possible violations of federal securities laws.
  • On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240412578742/en/

The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

Retrieved on: 
Mittwoch, April 10, 2024
Class Action Lawsuit, Professional Services, Legal, AbbVie, Suite, Research, Law, IPR, ABBV, GAAP, News

The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
  • If you are a shareholder who suffered a loss, click here to participate.
  • On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

Retrieved on: 
Freitag, April 12, 2024
Patient, ABBV, Safety, AbbVie, MD, Migraine, Freedom, European, Disease, Week, CGRP, Anesthesia, Neurology, Headache, PROGRESS, Harvard Medical School, Interim, Pharmaceutical industry

NORTH CHICAGO, Ill., April 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcomes, including reduction in monthly acute medication use days.

Key Points: 
  • The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified.
  • These results also support improvements in key efficacy outcomes, including reduction in monthly acute medication use days.
  • Overall safety results were consistent with the known safety profile of atogepant 60 mg, and no new safety signals were identified.
  • "Patients should accept nothing less than migraine freedom, and the long-term safety and efficacy shown in this interim analysis marks another step toward that goal."

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)

Retrieved on: 
Montag, April 1, 2024
AbbVie, AstraZeneca, THL, ABBV, IPO, Thomas H. Lee Partners, Brodsky, AZN, CVR, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, AdTheorent will be acquired by Cadent, LLC (“Cadent”).
  • The Company’s common stockholders will receive cash consideration of $3.21 per share.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

Retrieved on: 
Montag, April 1, 2024
Research, Growth, JV, Amazon, Health, Partnership, International, Webcast, ABBV, Foot, Acquisition, Cellulite, OTC, Marketing, Advertising, Stada Arzneimittel, Video game

Adam Levy, NEXGEL’s Chief Executive Officer, commented, “2023 was a record year for NEXGEL and transformational in many respects.

Key Points: 
  • Adam Levy, NEXGEL’s Chief Executive Officer, commented, “2023 was a record year for NEXGEL and transformational in many respects.
  • Our nearly 100% year-over-year revenue growth in 2023 was primarily driven by our branded products and contract manufacturing.
  • The increase in revenue was primarily due to sales growth in contract manufacturing of 166% and an increase in branded product revenue by approximately $427,000, or 52.4%, to $1.24 million.
  • For the fourth quarter of 2023, branded products revenue was $392,000, an increase of 104.2% year-over-year and 10.1% sequentially.